Orlistat
- Generic Name
- Orlistat
- Brand Names
- Alli, Xenical, Alli (previously Orlistat GSK)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H53NO5
- CAS Number
- 96829-58-2
- Unique Ingredient Identifier
- 95M8R751W8
- Background
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
- Indication
Orlistat is indicated for obesity management including weight loss and weight maintenance when used in combination with calorie reduction in overweight and obese adults; this indication applies to both the prescription formulation of 120 mg and the over-the-counter formulation of 60 mg. Orlistat in the 120 mg prescription formulation is also indicated to reduce the risk of weight regain following weight loss.
- Associated Conditions
- Weight Gain
- Associated Therapies
- Weight Reduction
Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility
- Conditions
- Infertility, Female
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 379
- Registration Number
- NCT02432209
- Locations
- 🇺🇸
Wayne State University, Southfield, Michigan, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea
- Conditions
- ObesityDiabetesObstructive Sleep Apnea
- Interventions
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Mid-Atlantic Epilepsy and Sleep Center, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT02069197
- Locations
- 🇺🇸
Mid-Atlantic Epilepsy and Sleep Center, LLC, Bethesda, Maryland, United States
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
- Conditions
- Type II Diabetes in Subjects BMI 27 to 32
- Interventions
- Procedure: Roux-en-Y Gastric Bypass (RYGB)Drug: Incretin analoguesDrug: XenicalDrug: SGLT2 inhibitorsDrug: DPP-4 Inhibitors
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Khoo Teck Puat Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02041234
- Locations
- 🇸🇬
Khoo Teck Puat Hospital, Singapore, Singapore
Comparison of MAG and Fish Oil Efficacy
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Société des Produits Nestlé (SPN)
- Target Recruit Count
- 46
- Registration Number
- NCT01797757
- Locations
- 🇨🇭
CHUV Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Pennington Biomedical Research Center
- Registration Number
- NCT01719419
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
- Conditions
- Type 1 Hyperlipoproteinemia
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT01675154
- Locations
- 🇺🇸
UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Conditions
- Gastric BandingType 2 Diabetes
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- East Carolina University
- Target Recruit Count
- 1
- Registration Number
- NCT01597531
- Locations
- 🇺🇸
Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States
The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)
- Conditions
- ObesityPolycystic Ovaries Syndrome
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 200
- Registration Number
- NCT01475019
- Locations
- 🇬🇷
Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece
Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 17
- Registration Number
- NCT01414465
- Locations
- 🇧🇷
LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
Survey on the Pharmacy Follow-up of Alli Purchasers
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT01387243
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.